drug · protein
octreotide LA
pre_registrationupdated 6mo agoby Camurus AB🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7- drugoctreotide acetate4 co-mentions · 4 sources
- drugoctreotide acetate DR4 co-mentions · 4 sources
- drugoctreotide acetate LA4 co-mentions · 4 sources
- drugBynfezia4 co-mentions · 4 sources
- companyTeva Pharmaceuticals USA Inc3 co-mentions · 3 sources
- tagRecall3 co-mentions · 3 sources
- tagApproval2 co-mentions · 1 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for acromegaly and 25 investigational indications.
targets
Somatostatin receptor
all catalysts(0)
nothing on the calendar yet
Trials studying octreotide LA
- phase3A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
- —An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
- phase3Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- phase3An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
- phase3Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
- phase3Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- phase3Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- phase3A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that